Aclarion, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
ACON$1.60-8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(5,344,487) | $(5,003,355) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 166,093 | 140,893 |
| Share-based compensation | 101,003 | 230,837 |
| Amendment of warrants | 48,087 | – |
| Non-cash settlements | 58,272 | – |
| Loss on exchange of debt | – | 1,073,317 |
| Loss on extinguishment of debt | – | 111,928 |
| Amortization of deferred issuance costs | – | 502,516 |
| Change in fair value related to warrants and derivative | (11,767) | (330,632) |
| Non-cash interest related to bridge funding | – | 58,002 |
| Change in operating assets and liabilities | ||
| Accounts receivable | (13,692) | (2,351) |
| Prepaids and other current assets | (164,100) | (329,306) |
| Accounts payable | (214,007) | (443,068) |
| Accrued and other liabilities | (162,168) | (326,399) |
| Note payable, net of discount | – | (31,129) |
| Net cash used in operating activities | (5,536,766) | (4,348,747) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Intangible assets – Patents | (154,639) | (261,220) |
| Fixed assets | (7,802) | – |
| Net cash used in investing activities | (162,441) | (261,220) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Public offering of common stock and warrants | 14,554,545 | – |
| Registered Direct offerings | 5,167,927 | – |
| Common stock cash issuance costs | (2,243,441) | (714,332) |
| Exercise of Series C warrants | 336,441 | – |
| Redemption of Series B Preferred stock | (1,213,590) | – |
| Issuance of common stock and warrants related to public offering, net deductions | – | 2,691,391 |
| Proceeds from common stock and warrant RegA+ offering | – | 529,254 |
| Proceeds from sales of C-Series preferred stock and warrants | – | 1,000,000 |
| Proceeds from equity line | – | 1,754,032 |
| Repayment of promissory notes | – | (300,974) |
| Bridge fund cash issuance costs | – | (23,375) |
| Preferred stock cash issuance costs | – | (35,000) |
| Net cash provided by financing activities | 16,601,882 | 4,900,996 |
| Net increase in cash and cash equivalents | 10,902,675 | 291,029 |
| Cash, cash equivalents and restricted cash, beginning of period | 463,661 | 1,031,069 |
| Cash, cash equivalents and restricted cash, end of period | $11,366,336 | $1,322,098 |
| Non-cash activities | ||
| Capitalization of Series B preferred stock dividends | $5,425 | $– |
| Capitalization of Series C preferred stock dividends | $1,258 | $– |
| Conversion of Series C preferred stock to common stock | $548,534 | $– |
| Cashless exercise of B warrants to common stock | $9,539,081 | $– |
| Dividends accrued on preferred shares | $– | $12,142 |
| Exchange of indebtedness for preferred shares | $– | $930,052 |
| Issuance of common shares in exchange for debt | $– | $1,771,606 |
| Issuance of bridge fund commitment shares | $– | $33,297 |
| Accrued issuance costs related to preferred stock | $– | $55,000 |
| Accrued issuance costs related to common stock | $– | $94,733 |
| Designation of prepaid expenses to common stock issuance costs | $– | $919,439 |
| Issuance of common shares related to restricted stock units | $– | $216,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.